Your session is about to expire
← Back to Search
Empagliflozin for Kidney Transplant Complications (CREST-KT Trial)
CREST-KT Trial Summary
This trial is testing a diabetes medication in people who have had a kidney transplant. Half the patients have diabetes and half don't. The patients will be given either the medication or a placebo and monitored to see if the medication improves outcomes.
CREST-KT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCREST-KT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CREST-KT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a solid organ transplant.I have had more than 2 UTIs in the last year.I am currently taking SGLT2 inhibitors.I am not on blood thinners except for low-dose aspirin.You have antibodies from a specific donor in your blood before joining the study.It has been 1 to 5 years since my kidney transplant.I have had a genital infection in the last year.My kidney function, measured by eGFR, is at least 30ml/min/1.73m^2.I have Type 1 diabetes.You have had an allergic reaction or could not tolerate SGLT2 inhibitor medication before.I have had a severe rejection reaction or a high rejection score.I am an uncircumcised man.I am on standard drugs to suppress my immune system.Your Hemoglobin A1c level is higher than 12%.
- Group 1: Arm I: With Type II Diabetes
- Group 2: Arm 2: Without Diabetes
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what purpose is Arm 2: Without Diabetes most typically employed?
"Arm 2: Without Diabetes is an oft-used pharmaceutical to treat diabetes. Additionally, it has been known to be effective in managing other issues such as inadequate response to monotherapy and lifestyle modifications like diet and exercise."
Are there any vacancies for this research study at the moment?
"Per the clinicaltrials.gov website, this medical study is actively in search of participants. The date of its initial posting was July 25th 2022 and most recently updated on September 26th 2022."
Has a similar experiment been conducted previously?
"Currently, there are 63 ongoing trials concerning Arm 2: Without Diabetes in 50 countries across 235 cities. This research began back in 2014 when AstraZeneca sponsored a trial encompassing 700 participants to reach the N/A drug approval stage. Since then, 18452 studies have been conducted on this topic."
How many participants are engaged in this research?
"Affirmative, the information hosted on clinicaltrials.gov signals that this medical experiment is actively enlisting volunteers. Initially posted on July 25th 2022 and last updated September 26th of the same year, it seeks 72 individuals from a single site for study participation."
What are the implications of Arm 2: Without Diabetes for human health?
"Taking into account the safety data gathered from Phase 2 clinical trials, our team at Power assigned a score of 2 to Arm 2: Without Diabetes. This is due to the lack of efficacy information as compared with existing safety studies."
Share this study with friends
Copy Link
Messenger